Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer

the results of this study showed the promising survival outcomes in patients with genotype-matched therapy under public insurance, even in the castration-resistant prostate cancer setting. Further detection of promising therapeutic target gene is expected to increase the number of patients who reach genotype-matched therapies.